<DOC>
	<DOCNO>NCT02993133</DOCNO>
	<brief_summary>The main autoimmune bullous dermatosis pemphigus cicatricial pemphigoid . Pemphigus autoimmune dermatological disease characterize production anti-desmoclesin antibody 1 3 , affect skin mucous membranes.The cicatricial pemphigoid autoimmune dermatological disease , characterize production anti-zone antibody basal membrane characterize predominant mucosal involvement . Mycophenolic acid ( MPA ) increasingly use form corticosteroid . Despite increase use , pharmacokinetics autoimmune bullous dermatosis remain little studied .</brief_summary>
	<brief_title>Pharmacokinetics Study Mycophenolic Acid Patients With Autoimmune Bullous Dermatose , Pemphigus Cicatricial Pemphigoid .</brief_title>
	<detailed_description />
	<mesh_term>Pemphigus</mesh_term>
	<mesh_term>Pemphigoid , Bullous</mesh_term>
	<mesh_term>Pemphigoid , Benign Mucous Membrane</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Age &gt; = 18 year . Patient treat Mycophénolate Mofétil ( MMF ) per o ( Cellcept® ) autoimmune bullous dermatose ( pemphigus cicatricial pemphigoid ) least 30 day accord recommendation ( PNDS Pemphigus cicatricial pemphigoid HAS 2011 ) Patient able understand nature , purpose methodology study Patient affiliate French social security system equivalent Patient sign informed consent form Pregnant breastfeed woman woman childbearing potential without efficient contraception ( base declaration ) Patient legal protection . Patient deprive freedom Patient alter mental status psychiatric condition would interfere understand study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>